시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
간성뇌증 시장 보고서(2025년)
Hepatic Encephalopathy Global Market Report 2025
상품코드 : 1825408
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,661,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,629,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,596,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

간성뇌증 시장의 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 연평균 복합 성장률(CAGR) 5.5%로 22억 3,000만 달러로 성장할 전망입니다. 예측기간 동안의 성장은 고령화 인구 증가, 치료 옵션 급증, 건강 관리 인프라 지출 증가, 간성뇌증 치료 투자에 기인할 것으로 예상됩니다. 예측기간의 주요 동향으로는 새로운 치료법의 개발, 조사 및 임상시험, 간이식의 진보, 의약품의 혁신, 영양 및 식이 관리의 진보, 원격의료 및 원격 모니터링의 채용 등을 들 수 있습니다.

향후 5년간의 예측 성장률 5.5%는 과거 예측에서 0.1% 소폭 감소한 수치입니다. 이러한 성장세 둔화는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 무역 마찰은 인도와 캐나다에서 조달하는 락툴로스 제형과 암모니아 감소제의 가격을 상승시켜 복약 순응도를 낮추고 간질환 환자의 신경합병증을 악화시킬 수 있습니다. 또한 상호관세와 무역 긴장 증가와 제한으로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향이 더 광범위하게 늘어날 것으로 보입니다.

간질환의 유병률 증가는 향후 수년간 간성뇌증 시장의 성장을 가속할 것으로 예측됩니다. 간질환은 간에 영향을 미치고 그 기능을 손상시키는 모든 상태를 의미합니다. 간성뇌증과 같은 간질환의 치료는 증상을 완화하고, 질병의 진행을 늦추며, 간 기능을 개선하고, 기초 질환을 더 잘 관리함으로써 간성뇌증의 발생을 억제할 수 있습니다. 이로 인해 에피소드의 빈도와 중증도가 모두 감소하고 환자의 전반적인 QOL이 향상될 수 있습니다. 예를 들어, 2024년 4월 영국의 정부기관 Office for Health Improvement and Disparities는 간질환으로 인한 입원환자 수가 계속 증가하고 있으며, 2023 회계연도에는 인구 10만 명당 155.2명에 이르렀고 전년 150.6명에서 증가했다고 보고했습니다. 따라서 간질환의 유병률 증가는 간성뇌증 시장의 성장을 뒷받침하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

CSM
영문 목차

영문목차

Hepatic encephalopathy is a condition characterized by a decline in brain function resulting from severe liver disease. It is a reversible syndrome of impaired brain function in patients with advanced liver diseases. Treating hepatic encephalopathy (HE) involves managing the underlying liver disease, reducing ammonia levels in the blood and addressing neurological symptoms.

The main drug types of hepatic encephalopathy are antibiotics, laxatives, l-ornithine, l-aspartate and others. Antibiotics are a class of medications that are used to treat bacterial infections and helps lower the overall ammonia load in the body, which can contribute to the neurological symptoms associated with hepatic encephalopathy. The various route of administration including oral, intravenous and rectal which are distributed through various distribution channels such as hospital pharmacies, retail pharmacies and online pharmacies.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The hepatic encephalopathy market research report is one of a series of new reports from The Business Research Company that provides hepatic encephalopathy market statistics, including hepatic encephalopathy industry global market size, regional shares, competitors with a hepatic encephalopathy market share, detailed hepatic encephalopathy market segments, market trends and opportunities and any further data you may need to thrive in the hepatic encephalopathy industry. This hepatic encephalopathy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hepatic encephalopathy market size has grown steadily in recent years. It will grow from $1.72 billion in 2024 to $1.8 billion in 2025 at a compound annual growth rate (CAGR) of 4.5%. The growth in the historic period can be attributed to prevalence of liver diseases, growing awareness about hepatic encephalopathy, government initiatives, increasing new liver therapies.

The hepatic encephalopathy market size is expected to see strong growth in the next few years. It will grow to $2.23 billion in 2029 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to increasing ageing population, surge in treatment options, rising expenditure on healthcare infrastructure, investments on hepatic encephalopathy treatments. Major trends in the forecast period include launch of emerging therapies, research and clinical trials, advances in liver transplantation, pharmaceutical innovations, advances in nutrition and dietary management, adption of telemedicine and remote monitoring.

The forecast of 5.5% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions may inflate prices of lactulose formulations and ammonia-reducing drugs sourced from India and Canada, resulting in reduced medication adherence and worsening neurological complications for liver disease patients. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of liver diseases is expected to drive the growth of the hepatic encephalopathy market in the coming years. Liver disease refers to any condition that affects the liver and impairs its functionality. Treatments for liver diseases, such as those for hepatic encephalopathy, can help alleviate symptoms, slow the progression of the disease, improve liver function, and reduce the occurrence of hepatic encephalopathy by better managing underlying conditions. This can potentially decrease both the frequency and severity of episodes, improving patients' overall quality of life. For example, in April 2024, the Office for Health Improvement and Disparities, a government department in the UK, reported that hospital admissions for liver disease continued to rise, reaching 155.2 per 100,000 population in the financial year ending 2023, up from 150.6 the previous year. As such, the increasing prevalence of liver diseases is fueling the growth of the hepatic encephalopathy market.

Rising healthcare expenditures are expected to drive the growth of the hepatic encephalopathy market. Healthcare expenditures refer to the total spending on healthcare services, products, and activities over a specific period, which can be measured at the individual, community, national, or global level. Increased healthcare spending can positively affect the availability and development of hepatic encephalopathy treatments by supporting advancements in diagnosis, treatment options, awareness, and patient care. For example, in December 2023, the Centers for Medicare & Medicaid Services, a U.S.-based federal agency, reported that U.S. healthcare spending grew by 4.1% in 2022, reaching $4.5 trillion, surpassing the 3.2% increase seen in 2021. As a result, the rise in healthcare expenditures will contribute to the growth of the hepatic encephalopathy market.

Prominent companies operating in the hepatic encephalopathy market are actively involved in the development of innovative drugs aimed at treating hepatic encephalopathy. These efforts are driven by the desire to gain a competitive edge and reinforce their market position. For instance, in June 2023, Karolinska Development AB, a Sweden-based pharmaceutical company, introduced the novel GR3027 (golexanolone) for the treatment of hepatic encephalopathy. GR3027 is an orally administered small molecule classified as a GABAA-receptor-modulating steroid antagonist (GAMSA), designed to counteract positive GABAA-receptor modulation by endogenous neuroactive steroids. Additionally, the drug is undergoing clinical trials for the treatment of hepatic encephalopathy, specifically for chronic hepatic encephalopathy (CHE) in Phases I/IIa.

In September 2022, Genfit SA., a France-based biotechnology company, completed the acquisition of Versantis AG for an undisclosed sum. Through this strategic move, Genfit aims to expand its product pipeline to address other liver diseases characterized by unmet medical needs. Versantis, headquartered in Switzerland, is a biotechnology company specializing in the development of drugs for hepatic encephalopathy.

Major companies operating in the hepatic encephalopathy market are Umecrine Cognition AB, Bausch Health Companies Inc., Mallinckrodt Pharmaceuticals, Lupin Limited, Salix Pharmaceuticals, Norgine B.V., Ferring B.V., ASKA Pharmaceutical Co. Ltd., Vedanta Biosciences Inc., Gilead Sciences Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Bausch Health Companies Inc., Ochsner Health Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Cipla Limited, Amneal Pharmaceuticals LLC, Mallinckrodt PLC, Lupin Limited, Torrent Pharmaceuticals Ltd., Salix Pharmaceuticals Inc., ASKA Pharmaceutical Co. Ltd., Norgine B.V.

North America was the largest region in the hepatic encephalopathy market in 2024. The regions covered in hepatic encephalopathy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the hepatic encephalopathy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, and Spain.

The hepatic encephalopathy market consists of sales of lactulose, neomycin and zinc supplements. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hepatic Encephalopathy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hepatic encephalopathy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for hepatic encephalopathy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The hepatic encephalopathy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Hepatic Encephalopathy Market Characteristics

3. Hepatic Encephalopathy Market Trends And Strategies

4. Hepatic Encephalopathy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Hepatic Encephalopathy Growth Analysis And Strategic Analysis Framework

6. Hepatic Encephalopathy Market Segmentation

7. Hepatic Encephalopathy Market Regional And Country Analysis

8. Asia-Pacific Hepatic Encephalopathy Market

9. China Hepatic Encephalopathy Market

10. India Hepatic Encephalopathy Market

11. Japan Hepatic Encephalopathy Market

12. Australia Hepatic Encephalopathy Market

13. Indonesia Hepatic Encephalopathy Market

14. South Korea Hepatic Encephalopathy Market

15. Western Europe Hepatic Encephalopathy Market

16. UK Hepatic Encephalopathy Market

17. Germany Hepatic Encephalopathy Market

18. France Hepatic Encephalopathy Market

19. Italy Hepatic Encephalopathy Market

20. Spain Hepatic Encephalopathy Market

21. Eastern Europe Hepatic Encephalopathy Market

22. Russia Hepatic Encephalopathy Market

23. North America Hepatic Encephalopathy Market

24. USA Hepatic Encephalopathy Market

25. Canada Hepatic Encephalopathy Market

26. South America Hepatic Encephalopathy Market

27. Brazil Hepatic Encephalopathy Market

28. Middle East Hepatic Encephalopathy Market

29. Africa Hepatic Encephalopathy Market

30. Hepatic Encephalopathy Market Competitive Landscape And Company Profiles

31. Hepatic Encephalopathy Market Other Major And Innovative Companies

32. Global Hepatic Encephalopathy Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Hepatic Encephalopathy Market

34. Recent Developments In The Hepatic Encephalopathy Market

35. Hepatic Encephalopathy Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기